(MedPage Today) — The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday.
Indicated for adults with stubborn symptoms despite the use of…
Source link : https://www.medpagetoday.com/allergyimmunology/allergy/117745
Author :
Publish date : 2025-10-01 20:32:00
Copyright for syndicated content belongs to the linked Source.
